The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS

Omar Alkharabsheh; Aref Al-Kali; Salwa Saadeh; Rong He; David Viswanatha; Patricia T Greipp; Kaaren Reichard; Mithun Shah; Naseema Gangat; Mrinal M Patnaik; William Hogan; Mark R Litzow; Hassan Alkhateeb; Phuong L Nguyen

doi:10.1002/ajh.25239

The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS

Omar Alkharabsheh, Aref Al-Kali, Salwa Saadeh, Rong He, David Viswanatha, Patricia T Greipp, Kaaren Reichard, Mithun Shah, Naseema Gangat, Mrinal M Patnaik, William Hogan, Mark R Litzow, Hassan Alkhateeb, Phuong L Nguyen

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Journal	American Journal of Hematology
DOIs	https://doi.org/10.1002/ajh.25239
State	Accepted/In press - Jan 1 2018

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25239

Cite this

Alkharabsheh, O., Al-Kali, A., Saadeh, S., He, R., Viswanatha, D., Greipp, P. T., Reichard, K., Shah, M., Gangat, N., Patnaik, M. M., Hogan, W., Litzow, M. R., Alkhateeb, H., & Nguyen, P. L. (Accepted/In press). The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. American Journal of Hematology. https://doi.org/10.1002/ajh.25239

Alkharabsheh, O, Al-Kali, A, Saadeh, S, He, R, Viswanatha, D, Greipp, PT, Reichard, K, Shah, M, Gangat, N, Patnaik, MM , Hogan, W , Litzow, MR, Alkhateeb, H & Nguyen, PL 2018, 'The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS', American Journal of Hematology. https://doi.org/10.1002/ajh.25239

@article{3ace8410606a49bc8d77734b41fbeb06,

title = "The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS",

author = "Omar Alkharabsheh and Aref Al-Kali and Salwa Saadeh and Rong He and David Viswanatha and Greipp, {Patricia T} and Kaaren Reichard and Mithun Shah and Naseema Gangat and Patnaik, {Mrinal M} and William Hogan and Litzow, {Mark R} and Hassan Alkhateeb and Nguyen, {Phuong L}",

year = "2018",

month = jan,

day = "1",

doi = "10.1002/ajh.25239",

language = "English (US)",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS

AU - Alkharabsheh, Omar

AU - Al-Kali, Aref

AU - Saadeh, Salwa

AU - He, Rong

AU - Viswanatha, David

AU - Greipp, Patricia T

AU - Reichard, Kaaren

AU - Shah, Mithun

AU - Gangat, Naseema

AU - Patnaik, Mrinal M

AU - Hogan, William

AU - Litzow, Mark R

AU - Alkhateeb, Hassan

AU - Nguyen, Phuong L

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85054340309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054340309&partnerID=8YFLogxK

U2 - 10.1002/ajh.25239

DO - 10.1002/ajh.25239

M3 - Article

C2 - 30074268

AN - SCOPUS:85054340309

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

ER -

The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this